Ownership history in Ikarian Capital, LLC Β· 13 quarters on record
This page tracks every 13F SEC filing in which Ikarian Capital, LLC reported a position in FULCRUM THERAPEUTICS INC (FULC). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Ikarian Capital, LLC outperformed the S&P 500 by +84.3% annually on this FULC position. Timing score: 45% (5/11 decisions correct). Average cost basis: $8.40. Maximum drawdown during holding period: β75.6%.
π₯ Exceptional β beat the S&P 500 by 84.3% per year on this position.
8 quarters analyzed
β‘οΈ Neutral timing β roughly coin-flip accuracy on add/trim calls.
5 of 11 add/trim decisions correct
Best entry: $3.57 (2024 Q3) Β· Worst: $11.71 (2020 Q4)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
7 adds Β· 5 trims. Bought during 2 of 4 down-price quarters. π More buys than sells across the holding period.
π Ikarian Capital, LLC has been actively increasing its FULC allocation β a bullish signal from insiders.
Currently 1.21% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size